source
- Eli Lilly signs up to $370 million ion-channel collaboration with OmniAbEli Lilly announced a collaboration and licensing agreement with California-based drug discovery company OmniAb that will focus on ion-channel targets. The deal could see Lilly paying up to $370 m…
- Slate Medicines secures $245M financing and Nasdaq listing via reverse merger with Fulcrum TherapeuticsSlate Medicines, a North Carolina biotech, is moving toward a Nasdaq listing through a reverse merger with Fulcrum Therapeutics, six months after emerging from stealth. The transaction includes a…